This site is intended for Healthcare professionals only.

Aspirin prevents CVD and colorectal cancer: USPSTF Recommendation Statement


Aspirin prevents CVD and colorectal cancer: USPSTF Recommendation Statement

To update the 2009 U.S. Preventive Services Task Force (USPSTF) recommendations on aspirin use to prevent cardiovascular disease (CVD) events and the 2007 recommendation on aspirin and non-steroidal anti-inflammatory drug use to prevent colorectal cancer (CRC), the USPSTF reviewed 5 additional primary prevention trials of aspirin, mostly in individuals at low risk for CVD; multiple analyses of CRC follow-up data; and a comprehensive review of the potential harms of aspirin use.

The recommendations below apply to adults ≥ 40 years of age without known CVD or increased bleeding risk.

The USPSTF now recommends:

· Initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years. (B recommendation)

·  The decision to initiate low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 60 to 69 years who have a 10% or greater 10-year CVD risk should be an individual one. Persons who are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years are more likely to benefit. Persons who place a higher value on the potential benefits than the potential harms may choose to initiate low-dose aspirin. (C recommendation)

· The current evidence is insufficient to assess the balance of benefits and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults younger than 50 years.

· The current evidence is insufficient to assess the balance of benefits and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults aged 70 years or older.

REFERENCES

·     1Bibbins-Domingo K, on behalf of the U.S. Preventive Services Task Force. Aspirin use for primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016; 164: 836-45.

·      2Baigent C. Aspirin for disease prevention: Public policy or personal choice? Ann Intern Med. 2016; 164: 846-7.

The following two tabs change content below.
supriya kashyap

supriya kashyap

Supriya Kashyap Joined Medical Dialogue as Reporter in 2015 . she covers all the medical specialty news in different medical categories. She also covers the Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in medical filed. She is a graduate from Delhi University. She can be contacted at supriya.kashyap@medicaldialogues.in Contact no. 011-43720751
Source: self

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted
  1. Anything is welcome which scientifically reduces incidence of colorectal cancer.